Drugs / 3,4-methylenedioxymethamphetamine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05709353 | Sep 2023 → May 2026 | alcohol dependence, post-traumatic stress disorder | University of Sydney | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4-methylenedioxymethamphetamine | “The use of adjunctive pharmacotherapies, such as 3,4-methylenedioxymethamphetamine (MDMA), may serve to optimise gold standard interventions.” PMID 42409408 ↗ Jul 2026 |
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05709353 ↗ |